Graphite Bio: Funding, Investors & Team (Sep 2026)
At Graphite Bio, they are rapidly building a next-generation gene editing company that is driven to apply their breakthrough technology with urgency to advance gene replacement therapies and cures for people living with serious diseases. They stand apart through our ability to harness natural and highly precise cellular DNA repair machinery to achieve high efficiency, targeted gene integration to correct the underlying causes of diseases.
Graphite Bio has raised $150M across 1 funding round on record, the most recent a Series B of $150M announced in Mar 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Graphite Bio Company Profile and Key Stats
Latest funding round on record: Mar 2021.
Graphite Bio Funding Rounds
Graphite Bio Founders and Leadership Team
Contact details for the Graphite Bio team: 1 of 1 has an email address on file.
Start 14-day free trial →Graphite Bio Funding Compared to Other Biotechnology Startups
Graphite Bio's latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Graphite Bio in Biotechnology and South San Francisco
Companies Similar to Graphite Bio
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Graphite Bio Funding FAQs
What does Graphite Bio do?
At Graphite Bio, they are rapidly building a next-generation gene editing company that is driven to apply their breakthrough technology with urgency to advance gene replacement therapies and cures for people living with serious diseases. They stand apart through our ability to harness natural and highly precise cellular DNA repair machinery to achieve high efficiency, targeted gene integration to correct the underlying causes of diseases.
How much funding has Graphite Bio raised?
Graphite Bio has raised $150M across 1 round on record. The most recent is a Series B of $150M announced in Mar 2021.
When did Graphite Bio last raise funding?
Graphite Bio's most recent funding round on record is a Series B of $150M, announced in Mar 2021.
Who is the CEO of Graphite Bio?
Josh Lehrer is listed as CEO at Graphite Bio.
Where is Graphite Bio headquartered?
Graphite Bio is based in South San Francisco, California, United States.
How many employees does Graphite Bio have?
Graphite Bio is in the 51-100 employee band.
How does Graphite Bio's funding compare to other Biotechnology startups?
Graphite Bio's latest round of $150M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Graphite Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Graphite Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.